Rifampicin Breadcrumb Home Glossary Rifampicin Short description Rifampicin is an antibiotic especially used to treat mycobacterial infections. Detailed description Rifampicin inhibits the RNA polymerase – a bacterial enzyme needed for protein production. More about “Rifampicin” Jan 2025 Lancet Child Adolesc Health Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis Autoren Garcia-Prats AJ et al. Jan 2025 Open Forum Infect Dis Programmatic Diagnostic Accuracy and Clinical Utility of Xpert MTB/XDR in Patients With Rifampicin-Resistant Tuberculosis in Georgia Autoren Pfurtscheller T et al. Feb 2025 Int J Tuberc Lung Dis Safety of 3-month rifampicin-isoniazid TPT in child household contacts in a community-based intervention Autoren Tchakounte Youngui B et al. © UNITE4TB Mar 24 2025 Open letter: Experts call for urgent expansion of Pretomanid label A coalition of leading tuberculosis (TB) experts and medical societies—including scientists from the German Center of Infection Research (DZIF)—is calling for an urgent expansion of the European Aug 2024 Open Forum Infect Dis Reflex Xpert MTB/XDR Testing of Residual Rifampicin-Resistant Specimens: A Clinical Laboratory-Based Diagnostic Accuracy and Feasibility Study in South Africa Autoren Centner CM et al. May 2024 Respiration Treatment of MDR, Pre-XDR, XDR, and Rifampicin-Resistant Tuberculosis or in Case of Intolerance to at Least Rifampicin in Austria, Germany, and Switzerland Autoren Otto-Knapp R et al. Jun 2024 Clin Microbiol Infect Re: 'Availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe' by Lange et al Autoren Friesen I et al. Jun 2024 Clin Microbiol Infect Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe: author's response Autoren Lange C et al. Mar 2024 Clin Microbiol Infect Availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe Autoren Günther G et al. Nov 2023 Pneumologie [Treatment of MDR, pre-XDR, XDR and rifampicin resistant TB or in case of intolerance to at least rifampicin in Austria, Germany and Switzerland - Amendment to the Sk2-Guideline: TB in adulthood of the DZK on behalf of the DGP] Autoren Otto-Knapp R et al. Pagination < Zurück Current page 1 Seite 2 Seite 3 Seite 4 Seite 1 Seite 2 Seite 3 Seite 4 Next page ››
Jan 2025 Lancet Child Adolesc Health Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis Autoren Garcia-Prats AJ et al.
Jan 2025 Open Forum Infect Dis Programmatic Diagnostic Accuracy and Clinical Utility of Xpert MTB/XDR in Patients With Rifampicin-Resistant Tuberculosis in Georgia Autoren Pfurtscheller T et al.
Feb 2025 Int J Tuberc Lung Dis Safety of 3-month rifampicin-isoniazid TPT in child household contacts in a community-based intervention Autoren Tchakounte Youngui B et al.
Aug 2024 Open Forum Infect Dis Reflex Xpert MTB/XDR Testing of Residual Rifampicin-Resistant Specimens: A Clinical Laboratory-Based Diagnostic Accuracy and Feasibility Study in South Africa Autoren Centner CM et al.
May 2024 Respiration Treatment of MDR, Pre-XDR, XDR, and Rifampicin-Resistant Tuberculosis or in Case of Intolerance to at Least Rifampicin in Austria, Germany, and Switzerland Autoren Otto-Knapp R et al.
Jun 2024 Clin Microbiol Infect Re: 'Availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe' by Lange et al Autoren Friesen I et al.
Jun 2024 Clin Microbiol Infect Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe: author's response Autoren Lange C et al.
Mar 2024 Clin Microbiol Infect Availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe Autoren Günther G et al.
Nov 2023 Pneumologie [Treatment of MDR, pre-XDR, XDR and rifampicin resistant TB or in case of intolerance to at least rifampicin in Austria, Germany and Switzerland - Amendment to the Sk2-Guideline: TB in adulthood of the DZK on behalf of the DGP] Autoren Otto-Knapp R et al.
